Anti-SPARC oligopeptide inhibits laser-induced CNV in mice

Vision Research

Volumn 50, Issue 7, 2010, Pages 674-679

  Uehara, Hironori ^a   Luo, Ling ^a   Simonis, Jacquelyn ^a   Singh, Nirbhai ^a   Taylor, Ethan Will ^b   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Age related macular degeneration (AMD); Choroidal neovascularization (CNV); FLT 1; SPARC; VEGF

Indexed keywords

AGENTS ACTING ON THE EYE; ARGINYLASPARAGINYLTYROSYLVALYLASPARTYLMETHIONYLPHENYLALANYLLYSINE; LYSYLPHENYLALANYLMETHIONYLASPARTYLVALYLTYROSYLASPARAGINYLARGININE; OSTEONECTIN; PHOSPHATE BUFFERED SALINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; LASER COAGULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; INTRAVITREAL INJECTIONS; LASERS; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; OSTEONECTIN; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77950521269     PISSN: 00426989     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.visres.2009.12.003     Document Type: Article

References (34)

1. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443(7114):993-997.
2. Amin R., Puklin J.E., Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Investigative Ophthalmology and Visual Science 1994, 35(8):3178-3188.
3. Arnold S.A., Brekken R.A. SPARC: A matricellular regulator of tumorigenesis. Journal of Cell Communication and Signaling 2009.
4. Bellner L., Vitto M., Patil K.A., Dunn M.W., Regan R., Laniado-Schwartzman M. Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin. Experimental Eye Research 2008, 87(3):268-278.
5. Bornstein P., Sage E.H. Matricellular proteins: Extracellular modulators of cell function. Current Opinion in Cell Biology 2002, 14(5):608-616.
6. Bussolati B., Dunk C., Grohman M., Kontos C.D., Mason J., Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. American Journal of Pathology 2001, 159(3):993-1008.
7. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001, 7(5):575-583.
8. Chandrasekaran V., Ambati J., Ambati B.K., Taylor E.W. Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein. Journal of Molecular Graphics & Modelling 2007, 26(4):775-782.
9. Chang T.S., Bressler N.M., Fine J.T., Dolan C.M., Ward J., Klesert T.R. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Archives of Ophthalmology 2007, 125(11):1460-1469.
10. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255(5047):989-991.
11. Epstein R.J., Stulting R.D., Hendricks R.L., Harris D.M. Corneal neovascularization: Pathogenesis and inhibition. Cornea 1987, 6(4):250-257.
12. Folkman J. What is the evidence that tumors are angiogenesis dependent?. Journal of the National Cancer Institute 1990, 82(1):4-6.
13. Francki A., McClure T.D., Brekken R.A., Motamed K., Murri C., Wang T., et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry 2004, 91(5):915-925.
14. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004, 351(27):2805-2816.
15. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Research 2001, 61(3):1207-1213.
16. Hiscott P., Hagan S., Heathcote L., Sheridan C.M., Groenewald C.P., Grierson I., et al. Pathobiology of epiretinal and subretinal membranes: Possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye 2002, 16(4):393-403.
17. Kearney J.B., Ambler C.A., Monaco K.A., Johnson N., Rapoport R.G., Bautch V.L. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 2002, 99(7):2397-2407.
18. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. Journal of Biological Chemistry 1996, 271(13):7788-7795.
19. Keyt B.A., Nguyen H.V., Berleau L.T., Duarte C.M., Park J., Chen H., et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. Journal of Biological Chemistry 1996, 271(10):5638-5646.
20. Kupprion C., Motamed K., Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. Journal of Biological Chemistry 1998, 273(45):29635-29640.
21. Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A., Magnusson P., et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO Journal 2005, 24(13):2342-2353.
22. Motamed K., Funk S.E., Koyama H., Ross R., Raines E.W., Sage E.H. Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. Journal of Cellular Biochemistry 2002, 84(4):759-771.
23. Ng E.W., Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Canadian Journal of Ophthalmology 2005, 40(3):352-368.
24. Nozaki M., Sakurai E., Raisler B.J., Baffi J.Z., Witta J., Ogura Y., et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. Journal of Clinical Investigation 2006, 116(2):422-429.
25. Oshima Y., Oshima S., Nambu H., Kachi S., Hackett S.F., Melia M., et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. Journal of Cellular Physiology 2004, 201(3):393-400.
26. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006, 355(14):1419-1431.
27. Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Investigative Ophthalmology and Visual Science 2003, 44(8):3578-3585.
28. Sakurai E., Taguchi H., Anand A., Ambati B.K., Gragoudas E.S., Miller J.W., et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Investigative Ophthalmology and Visual Science 2003, 44(6):2743-2749.
29. Schmitz-Valckenberg S., Fleckenstein M., Scholl H.P., Holz F.G. Fundus autofluorescence and progression of age-related macular degeneration. Survey of Ophthalmology 2009, 54(1):96-117.
30. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Advances in Cancer Research 1995, 67:281-316.
31. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. Journal of Biochemistry and Molecular Biology 2006, 39(5):469-478.
32. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research 2006, 312(5):549-560.
33. Smith W., Assink J., Klein R., Mitchell P., Klaver C.C., Klein B.E., et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001, 108(4):697-704.
34. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997, 91(5):695-704.